GlobeNewswire·Feb 12, 2026, 10:20 PM ET

OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

OKYO Pharma Limited (NASDAQ: OKYO) announced the pricing of an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share.
The underwriter holds a 30-day option to purchase up to an additional 1,622,250 ordinary shares at the same offering price.
Gross proceeds from the initial offering are approximately $20 million, rising to approximately $23 million if the option is fully exercised, before deducting expenses.
Net proceeds will be primarily used for clinical development of product candidates, general corporate purposes, & working capital.
Piper Sandler & Co. serves as the sole manager for the offering, which is expected to close on or about February 17, 2026.
The securities are being offered pursuant to a Form F-3 shelf registration statement filed with the SEC on February 2, 2026, & declared effective on February 10, 2026.
OKYO recently completed a Phase 2 trial of its flagship drug urcosimod for neuropathic corneal pain (NCP) & plans to initiate a ~150 subject Phase 2b/3 study in the first half of 2026.